Overview


According to FutureWise analysis the market for Neuroendocrine Carcinoma Treatment in 2023 is US$ 1.84 billion, and is expected to reach US$ 3.46 billion by 2031 at a CAGR of 8.22%.

Neuroendocrine tumor is a malignant and a rare disorder that covers over one percent of all the malignant disorders. Neuroendocrine carcinoma develops in different organs like intestines, kidneys, lungs, GI tract and brain. This cancer type occurs in the neuroendocrine system of humans and produces hormones that are like neuroendocrine cells. As per the America Society of Clinical Oncology, over 11,000 people in the United States are diagnosed with neuroendocrine carcinoma every year. Furthermore, as pe the U.S Surveillance Epidemiology and End Results Register, the prevalence of gastrointestinal neuroendocrine carcinoma has risen by over 300% as compared to 1981, thus offering an opportunity for neuroendocrine carcinoma treatment market growth. Additionally, growing investments in research and development for creating next-gen sequencing tools that are cost-effective and are used for developing advanced cancer therapies. With an increase in the number of clinical trials, this market is anticipated to witness substantial growth over the next few years.

There are various treatment alternatives available for the neuroendocrine carcinoma like radiation therapy, chemotherapy and surgery. 5-Fluorouracil and Streptozocin are some of the drugs that are used for treating this cancer. Many key players are constantly making efforts in developing targeted therapies, thereby propelling the proliferation of the market. Targeted drugs like Sunitinib and Everolimus are used for the treatment of this cancer. Such a variety of drug alternatives for treatment shall bolster the proliferation of the market.

  • Novartis AG
  • Amgen Inc.
  • Boehringer Ingelheim GmbH
  • Dauntless Pharmaceuticals
  • Hutchison MediPharma Limited
  • AVEO Pharmaceuticals Inc.
  • Chiasma Inc.
  • Aegis Therapeutics
  • Ispen
  • Progenics Pharmaceuticals, Inc.
  • Tarveda Therapeutics
  • Pfizer
  • Jubilant Life Sciences Ltd.(Jubilant DraxImage)
  • AbbVie Inc.
  • Delcath Systems Inc.
  • Exelixis, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Site

  • Lung
  • Gastrointestinal
  • Pancreas
  • Brain
  • Others

By Diagnostic Tools

  • Biopsy
  • Imaging
    • X-Ray
    • PET Scan
    • CT Scan
    • Others
  • Serology
    • Blood Tests
    • Molecular Tests
    • Urine Tests
    • Others
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

The market is classified into site, diagnostic tools and region. The site segment is fragmented into lung, gastrointestinal, pancreas, brain and others. The gastrointestinal segment accounted for the largest neuroendocrine carcinoma treatment market share and this can be attributed to unhealthy dietary choices leading to GI tract issues. Radiofrequency ablation is the only alternative for pancreatic neuroendocrine carcinoma tumor, and this shall bolster the augmentation of the market. On the other hand, disadvantages like tumor spread, bleeding and pancreatic fistula are predicted to restrain the market growth. The diagnostic tools segment is diversified into biopsy, imaging, serology and others. The serology segment is further divided into blood test, molecular tests, urine test and others. The imaging segment is categorised into X-ray, PET scan, CT scan and others. The increased acceptance of novel diagnostic imaging methods that are capable of detecting minute and clinically insignificant tumors shall contribute in the growth of the market.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key market trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the global neuroendocrine carcinoma treatment market by site, by diagnostic tools and by region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Neuroendocrine Carcinoma Treatment Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Neuroendocrine Carcinoma Treatment Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Neuroendocrine Carcinoma Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Neuroendocrine Carcinoma Treatment Market, By Site Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Lung
        2. Gastrointestinal
        3. Pancreas
        4. Brain
        5. Others

  • 8.   Neuroendocrine Carcinoma Treatment Market, By Diagnostic Tools Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Biopsy
        2. Imaging
         2.1 . X-Ray
         2.2 . PET Scan
         2.3 . CT Scan
         2.4 . Others
        3. Serology
         3.1 . Blood Tests
         3.2 . Molecular Tests
         3.3 . Urine Tests
         3.4 . Others
        4. Others

  • 9.   North America Neuroendocrine Carcinoma Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Neuroendocrine Carcinoma Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Neuroendocrine Carcinoma Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Neuroendocrine Carcinoma Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Neuroendocrine Carcinoma Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Novartis AG
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Amgen Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Boehringer Ingelheim GmbH
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Dauntless Pharmaceuticals
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Hutchison MediPharma Limited
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. AVEO Pharmaceuticals Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Chiasma Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Aegis Therapeutics
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Ispen
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Progenics Pharmaceuticals Inc.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Tarveda Therapeutics
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Pfizer
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Jubilant Life Sciences Ltd.(Jubilant DraxImage)
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. AbbVie Inc.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Delcath Systems Inc.
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Exelixis, Inc.
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients